SAN DIEGO, Calif., March 30, 2022 — Bluestar Genomics, Inc., an early cancer detection company leading the development and commercialization of next-generation liquid biopsy approaches initially focused on non-invasive detection of high-mortality cancers through a standard blood draw, today announced that its Chief Executive Officer David Mullarkey will participate in the Goldman Sachs fireside chat “The New Guard: Privates Leading The Disruption in Healthcare” on April 7, 2022 at 1:00 p.m., Eastern time.
“It’s an honor to participate in this discussion and I look forward to sharing insights into how the convergence of genomic science and technology is advancing liquid biopsy to become a standard of care in cancer management,” said Mullarkey. “Our first test for the detection of pancreatic cancer, awarded by the FDA with a breakthrough device designation, is just one example of how we can fulfill the promise of early cancer detection from a standard blood draw to transform the management of high-mortality cancers and ultimately help save lives.”
More than 600,000 people died from cancer last year in the United States, according to the American Cancer Society. This is in large part because some difficult-to-find cancers are found too late, when treatments are limited.
About Bluestar Genomics
Bluestar Genomics is an early cancer detection company focused on the development and commercialization of non-invasive epigenomic tests to detect cancer through a standard blood draw, earlier than existing methods and when the disease is still treatable. The company uses its patent-protected epigenomic platform that combines best-in-class bioinformatics and genomic technologies to analyze individuals’ changing biology that is yet to produce symptoms. Leveraging its novel liquid biopsy technology, Bluestar Genomics is initially focused on high-mortality cancers with the greatest need for early detection, starting with pancreatic and women’s cancers. With locations in San Diego and the San Francisco Bay Area, Bluestar Genomics collaborates with top research institutions and is supported by multiple global healthcare and technology investors and pharmaceutical collaborations.
